Cas:5240-95-9 Noricaritin manufacturer & supplier

Chemical Name:Noricaritin

CAS.NO:5240-95-9

Synonyms:4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-hydroxyphenyl)-;nor-icaritin;3,5,7-Trihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one;Noricaritin

Molecular Formula:C₂₀H₂₀O₇

Molecular Weight:372.369

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:650.2±55.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.700

PSA:131.36000

Exact Mass:372.120911

LogP:2.41

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-hydroxyphenyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Noricaritin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,nor-icaritin Use and application,3,5,7-Trihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one technical grade,usp/ep/jp grade.

Related News: The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction. 3-Carbamoyl-4-propoxy-benzoesaeure-(1) manufacturers The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. Acetic acid, bromo-, 4-chlorophenyl ester suppliers A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. (1S,8aS,9R,11R,12aS,13S,14S)-13-hydroxy-11-methyldodecahydro-1,9-ethanopyrido[2,1-j]quinolin-14-yl acetate vendor & factory Natural Biogenex, a 100 per cent subsidiary of Natural Capsules, is speeding up its efforts to manufacture active pharmaceutical ingredients (APIs) following the recent grant from Union government’s production linked incentive (PLI) scheme to offset the import dependence. ,The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually.